Filing Details
- Accession Number:
- 0001104659-23-042170
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-04-05 16:17:52
- Reporting Period:
- 2023-04-03
- Accepted Time:
- 2023-04-05 16:17:52
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1604191 | First Wave Biopharma Inc. | FWBI | Pharmaceutical Preparations (2834) | 464993860 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1697536 | Sarah Romano | C/O First Wave Biopharma, Inc 777 Yamato Road, Suite 502 Boca Raton FL 33431 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2023-04-03 | 1,975 | $2.50 | 19,453 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct |
Footnotes
- The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
- The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.41 to $2.60. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- Includes unvested RSUs.
- All amounts reflect the 1:7 reverse stock split effective as of January 18, 2023